Outcomes of surveillance VS. adjuvant chemotherapy for patients with STAGE IA and IB NON-seminomatous testicular germ-cell tumors.

Authors:

Abstract
E16051 Background: Approximately 50-60% of nonseminomatous germ-cell tumors (NSGCT) present with clinical stage I (CS I). Initial active surveillance, adjuvant chemotherapy and retroperitoneal lymph node dissection (RPLND) are acceptable three treatment options for these patients, but there is no uniform consensus. In this study, outcomes of active surveillance and adjuvant chemotherapy were compared in CS I NSGCT. Methods: A total of 201 patients with CS I NSGCT after orchiectomy in Turkey were included. Outcomes of active surveillance and adjuvant chemotherapy were retrospectively analyzed. The prognostic factors and the factors predicting relapse were evaluated. Results: Of the 201 patients, 110 (54.7) received adjuvant chemotherapy, while the remaining 91 patients (45.3%) underwent surveillance. Relapses were significantly higher for patients underwent surveillance compared to adjuvant chemotherapy group (18.3% vs. 1.2%, p < 0.001). The five-year disease-free survival (DFS) rate for patients who were treated with adjuvant chemotherapy were significantly better than surveillance group (97.6% vs. 80.8%, respectively; p < 0.001), but overall survival (OS) rates were similar. Univariate analysis showed that the presence of vascular invasion and treatment option for DFS and pT stage, invasion of rete testis, and the presence of relapse for OS were significant prognostic factors. Multivariate analysis revealed that the treatment strategy was an independent prognostic factor for DFS (p < 0.001). A logistic regression analysis demonstrated that treatment options (p = 0.031), EC > %50 (p = 0.013) and tumor diameter (p = 0.016) were found to be an independent factor for predicting relapse. Conclusions: Our results indicate that adjuvant chemotherapy is associated with improved DFS compared with surveillance for CS I NSGCT. The treatment strategy is an important prognostic indicator for DFS and a predictive factor for relapse. Although adjuvant chemotherapy seems to be a suitable treatment for patients with risk factors for relapse, surveillance is still feasible management option. More reliable predictive factors are needed to make treatment decisions.